3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
420
Precursor Cell Lymphoblastic Leukemia-Lymphoma
126
Neoplasms, Plasma Cell
74
Recurrence
70
Lymphoma
57
Leukemia
54
Neoplasms
46
Immunoglobulin Light-chain Amyloidosis
38
Burkitt Lymphoma
37
Vomiting
36
Lymphoma, Mantle-Cell
32
Lymphoma, Large B-Cell, Diffuse
31
Nausea
29
Lymphoma, Non-Hodgkin
28
Breast Neoplasms
22
Waldenstrom Macroglobulinemia
21
Lymphoma, Follicular
21
Hodgkin Disease
21
Leukemia, Lymphocytic, Chronic, B-Cell
20
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
17
Neoplasm Metastasis
17
Prostatic Neoplasms
16
Lymphoma, Extranodal NK-T-Cell
16
Amyloidosis
16
Leukemia, Myeloid, Acute
15
Smoldering Multiple Myeloma
14
Lymphoma, B-Cell, Marginal Zone
13
Lung Neoplasms
11
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma, B-Cell
10
Interventions
prednylidene
1
merphos
1
ixazomib
1
deltacortene
1
daratumumab
1
belantamab mafodotin
1
Vincristine
1
Rituximab
1
Prednisone
1
Methotrexate
1
Hydrocortisone
1
Etoposide
1
Doxorubicin
1
Dexamethasone
1
Cytarabine
1
Cyclophosphamide
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Plasmablastic Lymphoma
×
Dexamethasone
×
Clear all
NCT04915248
2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled